Direct AMP-activated protein kinase activators: A review of evidence from the patent literature

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 12, 2012, Pages 1467-1477

  Giordanetto, Fabrizio ^a   Karis, David ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Allosteric activator; AMP activated protein kinase; AMPK direct activation; Cancer; Metabolic disorder

Indexed keywords

4 HYDROXY 5 CARBOXAMIDE IMIDAZOLE; 5 ACETYLOXY 1,4 DIHYDROQUINOXALINE 2,3 DIONE; 5 HYDROXY 1,4 DIHYDROQUINOXALINE 2,3 DIONE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ALPHA1BETA1GAMMA1 AMP ACTIVATED PROTEIN KINASE; ALPHA2BETA2GAMMA1 AMP ACTIVATED PROTEIN KINASE; BENZIMIDAZOLE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; IMIDAZO[4,5 B]PYRIDINE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXINDOLE; PYRIDONE DERIVATIVE; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; THIENO[2,3 B]PYREDINEDIONE DERIVATIVE; THIENOPYRIDINE DERIVATIVE; THIENOPYRIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; CHEMICAL COMPOSITION; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG FORMULATION; DRUG SCREENING; DRUG STRUCTURE; DYSLIPIDEMIA; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; HIGH THROUGHPUT SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATENT; PHYSICAL CHEMISTRY; REVIEW; STEREOCHEMISTRY;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; METABOLIC DISEASES; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84869837353     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.743994     Document Type: Review

References (72)

1. Dyck JRB, Gao G, Widmer J, et al. Regulation of 5'-AMP-activated protein kinase activity by the noncatalytic beta and g subunits. J Biol Chem 1996;271:17798-803
2. Davies SP, Hawley SA, Woods A, et al. Purification of the AMP-activated protein kinase on ATP-gamma-sepharose and analysis of its subunit structure. Eur J Biochem 1994;223:351-7
3. Woods A, Cheung PCF, Smith FC, et al. Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. J Biol Chem 1996;271:10282-90
4. Stapleton D, Mitchelhill KI, Gao G, et al. Mammalian AMP-activated protein kinase subfamily. J Biol Chem 1996;271:611-14
5. Cheung PCF, Salt IP, Davies SP, et al. Characterization of AMP-activated protein kinase g-subunit isoforms and their role in AMP binding. Biochem J 2000;346:659-69
6. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009;89:1028-78
7. Ignoul S, Eggermont J. CBS domains: Structure, function and pathology in human proteins. Physiol Cell Physiol 2005;289:C1369-78
8. Chen L, Wang J, Zhang Y, et al. AMP-activated protein kinase undergoes nucleotide-dependent conformational changes. Nat Struc Mol Biol 2012;19:716-18
9. Oakhill JS, Chen Z-P, Scott JW, et al. beta-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc Natl Acad Sci 2010;107:19237-41
10. Oakhill JS, Steel R, Chen Z-P, et al. AMPK is a direct adenylate charge-regulated protein kinase. Science 2011;332:1433-5
11. Davies SP, Helps NR, Cohen PT, et al. 5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett 1995;377:421-5
12. Xiao B, Sanders MJ, Underwood E, et al. Structure of mammalian AMPK and its regulation by ADP. Nature 2011;472:230-3
13. Scott JW, Hawley SA, Green KA, et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 2004;113:274-84
14. Suter M, Riek U, Tuerk R, et al. Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem 2006;281:32207-16
15. Adams J, Chen ZP, van Denderen BJ, et al. Intrasteric control of AMPK via the gamma1 subunit AMP allosteric regulatory site. Protein Sci 2004;13:155-65
16. Hardie DG, Ross FA, Hawley SA. AMPK: A nutrient and Energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-62
17. Salt IP, Palmer TM. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Exp Op Invest Drugs 2012;21:11561167
18. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci 2004;101:3329-35
19. Carattino MD, Edinger RS, Grieser HJ, et al. Epithelial sodium channel inhibition by AMP-activated protein kinase in oocytes and polarized renal epithelial cells. J Biol Chem 2005;280:17608-16
20. Klein H, Garneau L, Trinh NT, et al. Inhibition of the KCa3.1 channels by AMP-activated protein kinase in human airway epithelial cells. Am J Physiol Cell Physiol 2009;296:C285-95
21. Kongsuphol P, Cassidy D, Hieke B, et al. Mechanistic insight into control of CFTR by AMPK. J Biol Chem 2009;284:5645-53
22. Kreneisz O, Benoit JP, Bayliss DA, et al. AMP-activated protein kinase inhibits TREK channels. J Physiol 2009;587:5819-30
23. Hardie DG, Carling D, Gamblin SJ. AMP-activated protein kinase: Also regulated by ADP? Trends Biochem Sci 2011;36:470-7
24. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 2010;1804:581-91
25. Yun H, Ha J. AMP-activated protein kinase modulators: A patent review. (2006-2010). Exp Op Ther Pat 2011;21:983-1005
26. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
27. Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells ex pressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010;11:554-65
28. Kou R, Sartoretto J, Michel T. Regulation of Rac1 by simvastatin in endothelial cells: Differential roles of AMP-activated protein kinase and calmodulin-dependent kinase kinase-beta. J Biol Chem 2009;284:14734-43
29. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-43
30. Corton JM, Gillespie JG, Hawley SA, et al. 5-aminoimidazole-4-carboxamide ribonucleoside: A specific method for activating AMP-activated protein kinase in intact cells? FEBS J 2005;229:558-65
31. Fujii N, Jessen N, Goodyear LJ. AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab 2006;291:E877-7
32. Guigas B, Bertrand L, Taleux N, et al. 5-aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes 2006;55:865-74
33. Abbott Laboratories. Preparation of substituted thieno[2,3-b]pyridones as activators for AMP-activated kinase for the treatment of diabetes and obesity. 2005; US20050038068
34. Zhao G, Iyengar RR, Judd AS, et al. Discovery and SAR development of thienopyridones: A class of small molecule AMPK activators. Bioorg Med Chem Lett 2007;17:3254-7
35. Iyengar RR, Zhao G, Judd AS, et al. Discovery and SAR studies of thienopyridones: A class of small molecule AMPK activators. 233rd ACS National Meeting; 25 - 29 March 2007; MEDI-231 Chicago, IL, United States
36. Iyengar RR, Zhao G, Judd AS, et al. Discovery and SAR studies of thienopyridones: A class of small molecule AMPK activators. 230th ACS National Meeting; August 28 -September 1 2005; MEDI-377 Washington, DC, United States
37. Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metabol 2006;3:403-16
38. Goeransson O, McBride A, Hawley SA, et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 2007;282:32549-60
39. Sanders MJ, Ali ZS, Hegarty BD, et al. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 2007;282:32539-4
40. Scott JW, van Denderen BJW, Jorgensen SB, et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem Biol 2008;15:1220-30
41. Zhou Y, Wang D, Zhu Q, et al. Inhibitory effects of A-769662, a novel activator of AMP-activated protein kinase, on 3T3-L1 adipogenesis. Biol Pharm Bull 2009;32:993-8
42. Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211-21
43. Kim AS, Miller EJ, Wright TM, et al. A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol 2011;51:24-32
44. Moreno D, Knecht E, Viollet B, et al. A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. FEBS Lett 2008;582:2650-4
45. Benziane B, Bjoernholm M, Lantier L, et al. AMP-activated protein kinase activator A-769662 is an inhibitor of the Na+-K+-ATPase. Am J Physiol 2009;297:C1554-66
46. Treebak JT, Birk JB, Hansen BF, et al. A-769662 activates AMPK beta1-containing complexes but induces glucose uptake through a PI3-kinase-dependent pathway in mouse skeletal muscle. Am J Physiol 2009;297:C1041-52
47. Merck Patent GMBH. Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them. 2007; WO2007019914
48. Merck Patent GMBH. Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators and their preparation, pharmaceutical compositions, and use in the treatment of diseases. 2009; WO2009124636
49. Merck Patent GMBH. Preparation of thieno[2,3-b]pyridin-6-one derivatives as AMP-activated protein kinase (AMPK) activators. 2009; WO2009135580
50. Merck Patent GMBH. Imidazole derivatives as AMPK activators, their preparation, pharmaceutical compositions, and use in therapy. 2008; WO2008006432
51. Merck Patent GMBH. Preparation of quinoxalinediones as AMPK activators. 2009; WO2009152909
52. Mercury Therapeutics, Inc. AMP kinase modulators. 2009; WO2009100130
53. Blazquez C, Woods A, De Ceballos ML, et al. The AMP-activated protein kinase is involved in the regulation of ketone body production by astrocytes. J Neurochem 1999;73:1674-82
54. Merck Sharp & Dohme Corp., Metabasis Therapeutics, Inc. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. 2010; WO2010036613
55. Merck Sharp & Dohme Corp., Metabasis Therapeutics, Inc. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. 2010; WO2010047982
56. Merck Sharp & Dohme Corp., Metabasis Therapeutics, Inc. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. 2010; WO2010051176
57. Merck Sharp & Dohme Corp., Metabasis Therapeutics, Inc. Novel cyclic benzimidazole derivatives as AMP-activated protein kinase activators and anti-diabetic agents and their preparation. 2010; WO2010051206
58. Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents. 2011; WO2011106273
59. Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents. 2012; WO2012116145
60. GlaxoSmithKline LLC. Pyrrolopyridone derivatives as activators of AMPK and their preparation and use in the treatment of diseases. 2011; WO2011029855
61. GlaxoSmithKline LLC. Preparation of pyrrolo[3,2-d]pyrimidin-3-yl derivatives used as activators of AMPK. 2011; WO2011138307
62. Mirguet O, Bouillot A, Daugan A, et al. Discovery of AMPK direct activators for the treatment of diabetes. 243rd ACS National Meeting; 25 - 29 March 2012; MEDI-189 San Diego, CA, United States 63. GlaxoSmithKline LLC. 1H-pyrollo[3,2-d]pyrimidinedione derivatives. 2012; WO2012119979
63. GlaxoSmithKline LLC. Quinolinone derivatives. 2012; WO2012119978
64. F. Hoffmann-La Roche AG. Preparation of alkene oxindole derivatives as activators of AMP activated protein kinase. 2011; WO2011032320
65. F. Hoffmann-La Roche AG. Preparation of alkene oxindole derivatives as activators of AMP activated protein kinase. 2011; WO2011033099
66. F. Hoffmann-La Roche AG. Spiro-cyclopropane-indolinone derivatives as AMPK modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases. 2011; WO2011069298
67. F. Hoffmann-La Roche AG. Sprio indole-cyclopropane indolinones useful as AMPK modulators. 2011; WO2011070039
68. F. Hoffmann-La Roche AG. Preparation of 3,3-dimethyl-1,2,3,4- tetrahydroquinoline derivatives as activators of AMP-activated protein kinase (AMPK). 2011; WO2011128251
69. F. Hoffmann-La Roche AG. Preparation of novel tetrahydroquinoline derivatives as AMPK. 2012; WO2012001020
70. Poxel. Thieno [2,3-B] pyredinedione activators of AMPK and theraputic uses thereof. 2011; WO2011080277
71. Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having AMPK activating effect. 2012; WO2012033149
72. Pang T, Zhang Z-S, Gu M, et al. Small Molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J Biol Chem 2008;283:16051-60.